Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151778 | 0.91 | MCL1 (0.54) | MCL1ALOX5BCL2A1POLBMEN1 | |
| SCHEMBL18151709 | 0.88 | MCL1 (0.52) | MCL1BCL2BCL2L1BCL2A1POLB | |
| SCHEMBL18151707 | 0.83 | MCL1 (0.64) | MCL1BCL2BCL2L1BCL2A1SLC16A3 | |
| SCHEMBL18152544 | 0.79 | PLAU (0.51) | MCL1BCL2BCL2L1BCL2A1POLB | |
| SCHEMBL18152275 | 0.75 | MCL1 (0.55) | MCL1MEN1KMT2A | |
| SCHEMBL22213615 | 0.73 | MCL1 (0.64) | MCL1ALOX5BCL2BCL2L1BCL2A1 | |
| SCHEMBL7348029 | 0.73 | MEN1 (0.70) | MCL1BCL2BCL2L1BCL2A1POLB | |
| SCHEMBL22762666 | 0.72 | MCL1 (0.60) | MCL1BCL2BCL2L1BCL2A1POLB | |
| SCHEMBL18164555 | 0.72 | MCL1 (0.53) | MCL1BCL2BCL2L1BCL2A1SLC16A3 | |
| SCHEMBL18152212 | 0.71 | MCL1 (0.64) | MCL1ALOX5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | MCL1 1/4885ALOX5 3056/4885BCL2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.